ERI-3003 Market Summary

Key Factors Driving ERI-3003 Growth

1. Dual CD19/BCMA targeting for multiple myeloma

TPST-3003 is designed to target both CD19 and BCMA, potentially addressing different populations of malignant or disease-associated cells. BCMA is an established target in multiple myeloma, while CD19 may be expressed on certain B-cell populations associated with the disease. Dual targeting could potentially reduce the risk of treatment failure caused by loss or reduced expression of a single antigen. However, this is a development hypothesis, and clinical studies will be required to establish whether the approach improves response rates or durability compared with existing CAR-T therapies.

2. Off-the-shelf allogeneic CAR-T manufacturing

Autologous CAR-T therapies require collecting and modifying each patient's own T cells. TPST-3003 is designed to use donor-derived cells, potentially allowing treatment products to be manufactured in advance. If successful, this could shorten the time between treatment decision and infusion, reduce patient-specific manufacturing complexity, and improve availability. These benefits could be commercially important in relapsed or refractory multiple myeloma, where patients may have rapidly progressing disease. Actual manufacturing efficiency, product consistency, and cost advantages remain unproven for TPST-3003.

3. TRAC gene editing to reduce graft-versus-host risks

TPST-3003 incorporates a gene edit in the TRAC locus intended to inactivate the donor T-cell receptor. This is designed to reduce the risk of donor T cells attacking the recipient's healthy tissues, a complication known as graft-versus-host disease. If this strategy proves effective and safe, it could support broader use of donor-derived CAR-T products. Nevertheless, additional risks, including immune rejection, limited cell persistence, cytokine release syndrome, and other toxicities, will require evaluation during development.

4. Potential to leverage clinical data from the related TPST-2003 program

Tempest has indicated that TPST-3003 uses the same dual-targeting CAR structure as TPST-2003, an autologous CD19/BCMA CAR-T candidate being investigated in relapsed or refractory multiple myeloma. In February 2026, the company reported a 100% complete-response rate among six efficacy-evaluable patients in its ongoing REDEEM-1 study of TPST-2003. These preliminary findings may strengthen the scientific rationale for investigating the shared CAR-targeting architecture. However, the results belong to TPST-2003, not TPST-3003, and cannot establish the efficacy or safety of the allogeneic candidate.

5. Expansion opportunities in multiple myeloma and autoimmune diseases

TPST-3003's CD19/BCMA targeting strategy may have applications beyond multiple myeloma, potentially including selected B-cell-driven autoimmune diseases. Depleting disease-associated B cells and plasma cells is an area of growing scientific interest in autoimmune conditions where autoantibodies contribute to disease activity. These possibilities could expand its eventual addressable population if supported by preclinical research and clinical trials. At present, however, TPST-3003's publicly described development strategy remains early-stage, and no clinical efficacy has been established for this candidate in either cancer or autoimmune disease.

6. Tempest's development strategy and upcoming milestones

Tempest acquired the relevant therapeutic assets in a transaction announced in November 2025 and subsequently advanced them under its TPST naming system. Its March 2026 annual report described TPST-3003 as one of the company's first allogeneic CAR-T programs, intended to extend the biology of TPST-2003 into a potentially more scalable treatment format. The company has stated that process development and preclinical work are needed before an investigational new drug (IND) submission. These activities are essential milestones, but the candidate's progression will depend on preclinical findings, regulatory clearance, financing, and the availability of development partners.

ERI-3003 Recent Developments

In June 2026, Innovent Biologics announced that the first patient had been dosed in the Chinese pivotal Phase III clinical trial (TriadicMM-1) of its self-developed innovative anti-GPRC5D, BCMA and CD3 tri-specific antibody IBI3003 for the second to fifth-line treatment of patients with relapsed or refractory multiple myeloma (R/R MM). IBI3003 is China’s first self-developed anti-GPRC5D/BCMA/CD3 tri-specific antibody to enter the pivotal registrational Phase III clinical trial, aiming to bring a promising next-generation immunotherapy option for Chinese R/R MM patients.

“ERI-3003 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of ERI-3003 for potential indication like Multiple myeloma and Systemic lupus erythematosus in the 7MM. A detailed picture of ERI-3003’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the ERI-3003 for potential indications. The ERI-3003 market report provides insights about ERI-3003’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current ERI-3003 performance, future market assessments inclusive of the ERI-3003 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of ERI-3003 sales forecasts, along with factors driving its market.

ERI-3003 Drug Summary

ERI-3003, also referred to as TPST-3003, is an investigational allogeneic, dual-targeted chimeric antigen receptor T-cell (CAR-T) therapy being developed for the treatment of B-cell and plasma-cell malignancies, with potential applications in multiple myeloma and autoimmune diseases such as systemic lupus erythematosus (SLE). The therapy is designed to target B-cell maturation antigen (BCMA) and CD19, two proteins expressed by plasma cells and B-cell populations involved in the development and progression of certain hematological malignancies. By engineering T cells to recognize both targets, ERI-3003 aims to eliminate malignant cells expressing either antigen, potentially addressing tumor heterogeneity and reducing the likelihood of disease escape associated with targeting a single antigen. Unlike autologous CAR-T therapies manufactured from a patient's own T cells, ERI-3003 is designed to use T cells obtained from healthy donors, with genetic editing of the T-cell receptor alpha constant (TRAC) locus to inactivate the endogenous T-cell receptor. This modification is intended to reduce the risk of graft-versus-host disease and support the development of an off-the-shelf cellular therapy that could offer shorter manufacturing timelines and improved treatment accessibility. The report provides ERI-3003’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the ERI-3003 Market Report

The report provides insights into:

• A comprehensive product overview including the ERI-3003 MoA, description, dosage and administration, research and development activities in potential indication like Multiple myeloma and Systemic lupus erythematosus.
• Elaborated details on ERI-3003 regulatory milestones and other development activities have been provided in ERI-3003 market report.
• The report also highlights ERI-3003‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The ERI-3003 market report also covers the patents information, generic entry and impact on cost cut.
• The ERI-3003 market report contains current and forecasted ERI-3003 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The ERI-3003 market report also features the SWOT analysis with analyst views for ERI-3003 in potential indications.

Methodology

The ERI-3003 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ERI-3003 Analytical Perspective by DelveInsight

• In-depth ERI-3003 Market Assessment

This ERI-3003 sales market forecast report provides a detailed market assessment of ERI-3003 for potential indication like Multiple myeloma and Systemic lupus erythematosus in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted ERI-3003 sales data uptil 2034.

• ERI-3003 Clinical Assessment

The ERI-3003 market report provides the clinical trials information of ERI-3003 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

ERI-3003 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

ERI-3003 Market Potential & Revenue Forecast

• Projected market size for the ERI-3003 and its key indications
• Estimated ERI-3003 sales potential (ERI-3003 peak sales forecasts)
• ERI-3003 Pricing strategies and reimbursement landscape

ERI-3003 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• ERI-3003 Market positioning compared to existing treatments
• ERI-3003 Strengths & weaknesses relative to competitors

ERI-3003 Regulatory & Commercial Milestones

• ERI-3003 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

ERI-3003 Clinical Differentiation

• ERI-3003 Efficacy & safety advantages over existing drugs
• ERI-3003 Unique selling points

ERI-3003 Market Report Highlights

• In the coming years, the ERI-3003 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The ERI-3003 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ERI-3003’s dominance.
• Other emerging products for Multiple myeloma and Systemic lupus erythematosus are expected to give tough market competition to ERI-3003 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ERI-3003 in potential indications.
• Analyse ERI-3003 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted ERI-3003 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of ERI-3003 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of ERI-3003? How strong is ERI-3003’s clinical and commercial performance?
• What is ERI-3003’s clinical trial status in each individual indications such as Multiple myeloma and Systemic lupus erythematosus and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ERI-3003 Manufacturers?
• What are the key designations that have been granted to ERI-3003 for potential indications? How are they going to impact ERI-3003’s penetration in various geographies?
• What is the current and forecasted ERI-3003 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of ERI-3003 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to ERI-3003 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is ERI-3003? What is the duration of therapy and what are the geographical variations in cost per patient?